DocumentRX-4037
Issued
Read4 min

FDA Rejects Summit's Ivonescimab Over Missed Survival Endpoint

The FDA rejected Summit Therapeutics' ivonescimab after the Akeso-licensed bispecific missed a statistically significant overall survival benefit, despite delaying progression in a global lung cancer trial.

TAG C-7166 · 716 words on the filing

F.D.A. Rejects Closely Watched Lung Cancer Drug From China - The New York Times
F.D.A. Rejects Closely Watched Lung Cancer Drug From China - The New York TimesAnnie Spratt / unsplash

Summary of findings

  • FDA rejected ivonescimab for lack of a statistically significant overall survival benefit; Summit disclosed the decision Sunday.
  • The filing's global trial ran in the US, Canada, Europe and Asia and succeeded in delaying progression, but missed the survival endpoint.
  • A head-to-head trial against Keytruda in first-line advanced lung cancer is expected to report results before the end of this year.
  • Ivonescimab is in 17 late-stage studies worldwide; Merck and Pfizer are pursuing the same dual-mechanism approach.
  • Licensing deals like Akeso-Summit would remain permitted under proposed Trump administration rules barring US investment stakes in Chinese biotech.

The FDA has rejected ivonescimab, the China-invented bispecific antibody that Summit Therapeutics licensed from Akeso Biopharma, because the drug failed to show a statistically significant benefit in prolonging patients' lives. Summit disclosed the decision in a news release on Sunday. The agency declined to comment, which is standard practice for rejections.

Summit had sought approval only for certain patients with advanced lung cancer. The application rested on a global trial conducted in the United States, Canada, Europe and Asia, enrolling patients who had already tried a targeted treatment. The study compared ivonescimab plus chemotherapy against chemotherapy alone, and the drug succeeded in delaying cancer progression. That progression win was not enough; the survival endpoint failed.

What does the rejection mean for the filing strategy?

Summit has argued the survival miss simply reflected slow enrollment in the study. To bolster its case, the company sent the FDA analyses of longer-term outcomes that were not specified in the original research plan. Regulators were not persuaded. The episode is a familiar one for anyone tracking accelerated-pathway oncology filings: post-hoc analyses rarely rescue a missed primary-family endpoint, and here they did not.

Ivonescimab, given as an intravenous infusion, attacks a tumor on two fronts. It unleashes the immune system through one mechanism and cuts off the tumor's blood supply through another. Merck and Pfizer are developing medicines that take the same approach. Boosters had hoped ivonescimab could eventually displace Keytruda, the world's best-selling cancer medicine — a target cancer researchers worldwide have said the current trial results do not justify.

Why does this drug carry geopolitical weight?

The rejection lands amid a flurry of promising experimental drugs emerging from Chinese laboratories, fueling debate over whether the United States is ceding its longstanding dominance in biotechnology. Supporters note American patients can benefit from Chinese innovation. But Chinese drugmakers face fewer regulatory hurdles and move faster than their American counterparts — a dynamic that some U.S. lawmakers, investors and executives say puts domestic companies at a deep disadvantage.

The precedent for commercial success exists. Brukinsa and Carvykti, both invented in China, now generate over $1 billion in combined annual revenue in the United States, according to the source's characterization of the blood cancer market. For decades, top-selling drugs came from U.S. or European laboratories while China was regarded as a manufacturer of generics and ingredients. China's biotechnology industry has surged in recent years, producing patents, papers and cutting-edge experimental candidates.

Researchers have also voiced concern that drugs may not work as well in American patients as in Chinese patients, for reasons not fully understood. American regulators have insisted on seeing data in Western populations before approving cancer drugs from China — a stance this rejection does not soften.

Can the licensing model survive the politics?

Yes, at least under current proposals. To bring Chinese-invented drugs to American patients, Chinese companies sometimes sell U.S. rights to American drugmakers, as Akeso did with Summit. Those deals would continue to be permitted under new proposed regulations from the Trump administration prohibiting U.S. companies and investors from taking investment stakes in Chinese biotechnology. In-licensing stays open even as equity ties close.

What comes next for ivonescimab?

Globally, ivonescimab is being tested in 17 continuing, completed or planned late-stage studies, according to Summit. The drug is also being studied beyond lung cancer, including tumors of the colon, bladder and breast — the breadth that drove expectations in the first place.

The pivotal readout is a head-to-head trial expected to report results before the end of this year. It enrolled patients in the United States, China and other countries who have not yet tried treatment for their advanced lung cancer, and it will assess whether ivonescimab beats Keytruda at prolonging lives and extending time to progression. If that study succeeds, Summit is expected to seek FDA approval in the first-line setting.

In Sunday's release, Bob Duggan, a co-chief executive officer of Summit, said: "nothing changes with respect to our ever-growing belief in the opportunity for ivonescimab and our determination to advance ivonescimab's development." Every sponsor says something similar after a rejection. The year-end head-to-head data will either back that confidence or expose it.

via FDA industry wire (Google News) (Source)

Share this article:

More from Rebecca Stone

Rebecca Stone

Show full bio

Staff writer covering money, funding and market shifts around global pharmaceutical industry at PharmInsider.

18 articles

Linked filings

  1. T-7165
  2. K-1065
  3. C-4460
  4. P-9899
  5. P-6323

« Previous filingNext filing »